CMS Proposes Permanent Drug Price Negotiations for Medicare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: seekingalpha
- Negotiation Risk: The CMS proposed rule unveiled on June 12 aims to make Medicare drug price negotiations permanent, set to take effect in 2029, which has led to a decline in stock prices for drugmakers like Merck (MRK), Johnson & Johnson (JNJ), and Bristol Myers Squibb (BMY) due to increased negotiation risk.
- Market Impact: RBC analyst Trung Huynh warned that this development places significant pressure on pharmaceutical companies, particularly those relying on drugs like Darzalex, Opdivo, and Keytruda to extend their product lifecycles, potentially affecting their future revenue forecasts.
- Biosimilar Protection: In contrast, Regeneron's Eylea HD remains protected from this negotiation risk due to the existence of bona fide marketed biosimilars, exempting its entire product bundle from the proposed rule, which may help maintain its competitive edge in the market.
- Clinical Trial Results: Johnson & Johnson's multiple myeloma drug Talvey has shown a mortality risk reduction of up to 53% in late-stage trials, which may alleviate some investor concerns regarding the implications of the CMS proposal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.440
Low
95.00
Averages
119.53
High
139.00
Current: 115.440
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck's Capvaxive Vaccine Approved for Children by FDA
- Vaccine Label Expansion: Merck announced that its pneumococcal vaccine Capvaxive has received FDA approval for use in children aged 2 to 17, marking a significant expansion into the pediatric immunization market.
- Eligibility Criteria: The newly approved label stipulates that eligible children must have completed a primary pneumococcal vaccination series and have at least one chronic medical condition, ensuring the vaccine's effectiveness and safety for high-risk groups.
- Market Exclusivity: Capvaxive is now the only pneumococcal conjugate vaccine approved for this age group in the U.S., enhancing Merck's competitive position in the pediatric vaccine market and potentially driving sales growth.
- Strategic Implications: This approval not only broadens Capvaxive's market potential but also lays the groundwork for Merck's ongoing innovation and development in the vaccine sector, expected to boost overall company performance and shareholder returns.
See More
FDA Approves CAPVAXIVE Vaccine for Children at Risk
- FDA Approval for Expanded Indication: Merck announced that CAPVAXIVE has received FDA approval for use in children aged 2 to 17 with chronic conditions, providing additional protection and covering approximately 79% of invasive pneumococcal disease cases, significantly enhancing public health safety.
- Clinical Trial Support: Based on data from the Phase 3 STRIDE-13 trial, CAPVAXIVE demonstrated superior immune responses compared to PPSV23, showing significant protective effects against nine unique serotypes, thereby enhancing the vaccine's market competitiveness.
- Vaccine Coverage Scope: The 11 unique serotypes targeted by CAPVAXIVE account for 40% of invasive pneumococcal disease cases, highlighting its importance in high-risk pediatric populations and addressing unmet public health needs.
- Strategic Significance: This approval not only showcases Merck's commitment to public health but also provides a new preventive measure for children and adolescents, further solidifying the company's leadership position in the vaccine market.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Gilead's HIV Prevention Drug Filing Accepted by FDA
- FDA Filing Accepted: Gilead Sciences announced that the FDA has accepted its supplemental new drug application for the weekly oral HIV prevention drug Yeztugo, with a target action date of February 2, 2027, which will provide a more convenient prevention option for high-risk populations and further solidify its leadership in the HIV market.
- Clinical Data Support: The application for Yeztugo is backed by data from the PURPOSE 1 and PURPOSE 2 studies, demonstrating the strong efficacy of lenacapavir across diverse populations, successfully addressing the needs of different patients and potentially increasing Gilead's market share in HIV prevention.
- Sales Forecast Increase: Gilead has raised its 2026 sales forecast for Yeztugo to $1 billion, indicating confidence in the drug's market acceptance and sales potential, with expectations for it to achieve blockbuster status in its first full year post-launch.
- Collaborative Research Progress: Positive results from Gilead's collaboration with Merck in the ISLEND-1 and ISLEND-2 studies support the potential of a new once-weekly oral single-tablet treatment regimen, further advancing Gilead's HIV treatment pipeline and enhancing its competitive position in the market.
See More
Merck Signs $510M Drug Discovery Deal with Protillion Biosciences
- Significant Deal Value: Merck has signed a multi-target drug discovery and licensing agreement with Protillion Biosciences worth up to $510 million, which includes an undisclosed upfront payment and milestone payments, indicating a deep collaborative potential in drug development.
- Technological Integration Advantage: The deal leverages Protillion's proprietary Prot-MaP technology, which utilizes artificial intelligence to identify biologics with potential therapeutic value, further enhancing Merck's leadership in biopharmaceutical innovation.
- Increased Market Attention: This collaboration comes at a time when AI-driven drug discovery firms are gaining traction on Wall Street, marking Merck's strategic positioning in the biotech sector and potentially attracting more investor interest.
- Alignment with Industry Trends: The transaction aligns with Altaris's acquisition of Simulations Plus for $375 million in cash, reflecting a rising demand for drug discovery and development software, thereby driving innovation and investment in the biopharmaceutical industry.
See More
MRK Stock Slightly Declines Amid Market Trends
- Stock Performance: As of midday Tuesday, MRK's stock is down approximately 0.7%, indicating a cautious market sentiment towards the pharmaceutical sector, particularly when compared to competitors Eli Lilly and Johnson & Johnson.
- Industry Comparison: Eli Lilly and Johnson & Johnson are down about 0.1% and 1.3%, respectively, highlighting the overall pressure faced by the pharmaceutical industry, which could impact MRK's market performance and investor confidence.
- Three-Month Price History: The three-month price history chart for MRK shows its relative performance; despite the overall decline, attention should be paid to long-term trends and potential rebound opportunities.
- Analyst Opinions: Analysts' views on MRK align with market sentiment, reflecting a cautious outlook on the company's future growth, which may influence investor decisions and market liquidity.
See More
Merck's Capvaxive Vaccine Approved for Children by FDA
- Vaccine Label Expansion: Merck announced that its pneumococcal vaccine Capvaxive has received FDA approval for use in children aged 2 to 17, marking a significant expansion into the pediatric immunization market.
- Eligibility Criteria: The newly approved label stipulates that eligible children must have completed a primary pneumococcal vaccination series and have at least one chronic medical condition, ensuring the vaccine's effectiveness and safety for high-risk groups.
- Market Exclusivity: Capvaxive is now the only pneumococcal conjugate vaccine approved for this age group in the U.S., enhancing Merck's competitive position in the pediatric vaccine market and potentially driving sales growth.
- Strategic Implications: This approval not only broadens Capvaxive's market potential but also lays the groundwork for Merck's ongoing innovation and development in the vaccine sector, expected to boost overall company performance and shareholder returns.
See More
FDA Approves CAPVAXIVE Vaccine for Children at Risk
- FDA Approval for Expanded Indication: Merck announced that CAPVAXIVE has received FDA approval for use in children aged 2 to 17 with chronic conditions, providing additional protection and covering approximately 79% of invasive pneumococcal disease cases, significantly enhancing public health safety.
- Clinical Trial Support: Based on data from the Phase 3 STRIDE-13 trial, CAPVAXIVE demonstrated superior immune responses compared to PPSV23, showing significant protective effects against nine unique serotypes, thereby enhancing the vaccine's market competitiveness.
- Vaccine Coverage Scope: The 11 unique serotypes targeted by CAPVAXIVE account for 40% of invasive pneumococcal disease cases, highlighting its importance in high-risk pediatric populations and addressing unmet public health needs.
- Strategic Significance: This approval not only showcases Merck's commitment to public health but also provides a new preventive measure for children and adolescents, further solidifying the company's leadership position in the vaccine market.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Gilead's HIV Prevention Drug Filing Accepted by FDA
- FDA Filing Accepted: Gilead Sciences announced that the FDA has accepted its supplemental new drug application for the weekly oral HIV prevention drug Yeztugo, with a target action date of February 2, 2027, which will provide a more convenient prevention option for high-risk populations and further solidify its leadership in the HIV market.
- Clinical Data Support: The application for Yeztugo is backed by data from the PURPOSE 1 and PURPOSE 2 studies, demonstrating the strong efficacy of lenacapavir across diverse populations, successfully addressing the needs of different patients and potentially increasing Gilead's market share in HIV prevention.
- Sales Forecast Increase: Gilead has raised its 2026 sales forecast for Yeztugo to $1 billion, indicating confidence in the drug's market acceptance and sales potential, with expectations for it to achieve blockbuster status in its first full year post-launch.
- Collaborative Research Progress: Positive results from Gilead's collaboration with Merck in the ISLEND-1 and ISLEND-2 studies support the potential of a new once-weekly oral single-tablet treatment regimen, further advancing Gilead's HIV treatment pipeline and enhancing its competitive position in the market.
See More
Merck Signs $510M Drug Discovery Deal with Protillion Biosciences
- Significant Deal Value: Merck has signed a multi-target drug discovery and licensing agreement with Protillion Biosciences worth up to $510 million, which includes an undisclosed upfront payment and milestone payments, indicating a deep collaborative potential in drug development.
- Technological Integration Advantage: The deal leverages Protillion's proprietary Prot-MaP technology, which utilizes artificial intelligence to identify biologics with potential therapeutic value, further enhancing Merck's leadership in biopharmaceutical innovation.
- Increased Market Attention: This collaboration comes at a time when AI-driven drug discovery firms are gaining traction on Wall Street, marking Merck's strategic positioning in the biotech sector and potentially attracting more investor interest.
- Alignment with Industry Trends: The transaction aligns with Altaris's acquisition of Simulations Plus for $375 million in cash, reflecting a rising demand for drug discovery and development software, thereby driving innovation and investment in the biopharmaceutical industry.
See More
MRK Stock Slightly Declines Amid Market Trends
- Stock Performance: As of midday Tuesday, MRK's stock is down approximately 0.7%, indicating a cautious market sentiment towards the pharmaceutical sector, particularly when compared to competitors Eli Lilly and Johnson & Johnson.
- Industry Comparison: Eli Lilly and Johnson & Johnson are down about 0.1% and 1.3%, respectively, highlighting the overall pressure faced by the pharmaceutical industry, which could impact MRK's market performance and investor confidence.
- Three-Month Price History: The three-month price history chart for MRK shows its relative performance; despite the overall decline, attention should be paid to long-term trends and potential rebound opportunities.
- Analyst Opinions: Analysts' views on MRK align with market sentiment, reflecting a cautious outlook on the company's future growth, which may influence investor decisions and market liquidity.
See More
